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Tvrm4 mice, a model of autosomal dominant retinitis pigmentosa (RP), carry a mutation
of Rhodopsin gene that can be activated by brief exposure to very intense light.
Here, we test the possibility of an anatomical, metabolic, and functional recovery
by delivering to degenerating Tvrm4 animals, Myriocin, an inhibitor of ceramide de
novo synthesis previously shown to effectively slow down retinal degeneration in
rd10 mutants (Strettoi et al., 2010; Piano et al., 2013). Different routes and durations
of Myriocin administration were attempted by using either single intravitreal (i.v.) or
long-term, repeated intraperitoneal (i.p.) injections. The retinal function of treated and
control animals was tested by ERG recordings. Retinas from ERG-recorded animals
were studied histologically to reveal the extent of photoreceptor death. A correlation
was observed between Myriocin administration, lowering of retinal ceramides, and
preservation of ERG responses in i.v. injected cases. Noticeably, the i.p. treatment
with Myriocin decreased the extension of the retinal-degenerating area, preserved the
ERG response, and correlated with decreased levels of biochemical indicators of retinal
oxidative damage. The results obtained in this study confirm the efficacy of Myriocin
in slowing down retinal degeneration in genetic models of RP independently of the
underlying mutation responsible for the disease, likely targeting ceramide-dependent,
downstream pathways. Alleviation of retinal oxidative stress upon Myriocin treatment
suggests that this molecule, or yet unidentified metabolites, act on cellular detoxification
systems supporting cell survival. Altogether, the pharmacological approach chosen here
meets the necessary pre-requisites for translation into human therapy to slow down RP.
Keywords: retinitis pigmentosa, photoreceptor rescue, oxidative stress, Myriocin, mutation-independent
approach
INTRODUCTION
Recently, several experimental approaches have been proposed, aimed at recovering vision or
preventing vision loss caused by retinal degeneration. Photoreceptor degeneration may be initiated
by hundreds of different genetic mutations (RetNet, Retinal Information Network)1 and visually
impaired patients have reached an estimated number of over 20 million worldwide. Among
1http://www.sph.uth.tmc.edu/RetNet/
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these, individuals with retinitis pigmentosa (RP) develop a typical
phenotype characterized by rod degeneration with initial night
blindness and loss of peripheral vision. Subsequently, cones also
undergo degeneration, jeopardizing daytime vision and visual
acuity, eventually leading to legal blindness. RP is a family of
disorders typically caused by a single mutation in any of the
numerous genes, approximately 70 of which have been identified
so far. Thus, defining RP as a highly genetic heterogeneous
disease is justified by a large number of underlying mutations,
the different functions of the mutated genes, and the variable
mode of inheritance (Wright et al., 2010). About 40% of RP
cases show autosomal dominant inheritance and 25–30% of these
are attributable to mutations in RHO, the gene that codes for
rhodopsin, the photosensitive protein of rod photoreceptors.
A biochemical classification introduced in the 1990s (Sung
et al., 1991; Sung et al., 1993) identifies two classes of mutations
(I and II) on RHO. Class I mutations occur mainly near the
C-terminal of the protein, which still retains the ability to
bind to 11-cis-retinal and to form a functional chromophore
but cannot be adequately transported to the outer segment
and shows a constitutive activation or an increase in the
transducin activation (Mendez et al., 2003). The most common
class II mutations occur in the transmembrane or cytoplasmic
domains of the protein, resulting in incorrect rhodopsin folding,
retention in the endoplasmic reticulum, and inability to bind
to 11-cis-retinal. Dominant (or dominant-negative) mutations
are typically associated with a gain of function of the mutant
protein, as observed in the highly studied, highly representative,
P23H mutation, which causes retention of rhodopsin at the
endoplasmic reticulum (ER) level. The consequent unfolded
protein response (UPR) induction and proteosomal inhibition
leads to aggregation of high-molecular-weight oligomers, which
in turn form toxic intracellular inclusions (Lin et al., 2007;
Mendes and Cheetham, 2008; Athanasiou et al., 2018). P23H
and similar mutants are not easily approachable through gene
therapy, because they require simultaneous suppression of native
gene expression and supplementation with a wild-type (wt)
version of the gene (MacLaren et al., 2016). Other forms of
mutated rhodopsin (T4K, T4N, and T17M) show a lack of
glycosylation of the residue N15, which leads to light-dependent
retinal degeneration (Tam and Moritz, 2009).
The Tvrm4 mouse is an animal model particularly useful
to study RHO mutations and the complex link between
primary genetic defect and phenotype manifestation in order
to develop appropriate approaches for preserving vision in
humans with identical or similar genetic defects. The Tvrm4
strain constitutes an autosomal dominant RP model in which
a missense mutation of RHO gene modifies the amino acid
307, isoleucine (ATC), in asparagine (AAC) (Budzynski et al.,
2010). Peculiar characteristics of Tvrm4 mice are that they
do not express the retinal pathological phenotype and exhibit
normal rhodopsin levels if grown in normal housing conditions.
However, these mice undergo RP-type retinal degeneration
when exposed briefly (between 1 and 5 min) to strong white
light (12,000 lux), however harmless to wt controls. The
mutation leads to constitutively active mutated opsin (with
prolonged dark adaptation times) and exposure to light causes
an increase in the production of retinoid metabolites and
intermediates of the phototransduction cascade, as well as an
increase in mutant-free opsin levels that triggers processes
leading to photoreceptor death (Budzynski et al., 2010). Light
exposure for 1 to 5 min induces a massive photoreceptor
death after 24 h; degeneration is mainly limited to the center
of the retina while the peripheral area is less affected (effect
probably due to the geometry of the eye) (Gargini et al.,
2017). The peculiar features of Tvrm4 mutants, including
the possibility of inducing retinal degeneration once neuronal
development is completed, make them particularly useful for
the study of autosomal dominant RP and retinal remodeling
(Stefanov et al., 2019).
Using a widely exploited model of autosomal recessive RP, the
rd10 mouse mutant of phosphodiesterase (Chang et al., 2002;
Gargini et al., 2007), we have previously shown that long-term
topical administration of Myriocin, an inhibitor of the enzyme
serine-palmitoyl-CoA transferase involved in the first step of
sphingolipids (i.e., ceramides) synthesis, is effective in slowing
down the progression of the disease (Strettoi et al., 2010; Piano
et al., 2013).
The involvement of sphingolipid metabolism, and in
particular ceramide, in RP was first hypothesized in 2004.
Tuson and collaborators showed that mutations of the ceramide
kinase-like gene (CERKL) were associated with an autosomal
recessive RP model (RP26) (Tuson et al., 2004); the role of
CERKL in the retinal metabolism of sphingolipids was confirmed
later (Garanto et al., 2013).
It is the purpose of the present study to show that Myriocin
can be effective in more than one form of RP. To this aim, we
administered Myriocin using two distinct protocols (local and
systemic administration) immediately after light-induced retinal
degeneration in Tvrm4 mice.
The results show that Myriocin is effective in slowing
down retinal degeneration in this (fairly aggressive)
model of autosomal dominant RP. Surprisingly, Myriocin,
administered intraperitoneally for five consecutive days lowers
apoptotic processes and increases the anti-oxidant defenses of
the retinal cells.
MATERIALS AND METHODS
Animals
Animals were treated in accordance with Italian and European
institutional guidelines, following experimental protocols
approved by the Italian Ministry of Health (Protocol #14/D-
2014, CNR Neuroscience Institute; Protocol #653/2017-PR,
Department of Pharmacy, University of Pisa) and by the Ethical
Committees of both Institutions. Protocols adhere to the
Association for Research in Vision and Ophthalmology (ARVO)
statement for the use of animals in research.
Heterozygous (±) Tvrm4 mice (RhoTvrm4/Rho+, from now
on “Tvrm4 mice”) with a I307N (near C-terminus) mutation
of the rhodopsin gene (Rho) mice were used for this study
(Budzynski et al., 2010). Tvrm4 mutants are on a C57Bl6/J
background and exhibit no retinal phenotype unless exposed
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to bright light stimuli. Genotyping was performed following
Budzynski et al. (2010) and Jackson Laboratory’s indications and
only heterozygous mice were used for the experiments.
Induction of Retinal Degenerating
Phenotype and Pharmacological
Treatment
In this study we used young, adult mice aged 2–5 months,
thus outside the time window of full retinal development
(completed at around 30 days of age) and much younger
than the manifestation of cellular aging (12 months). The age
range chosen was already used in previous studies on Tvrm4
mutants, demonstrating that the light-induced damage is not
influenced by the age of the animal (Budzynski et al., 2010;
Gargini et al., 2017). Tvrm4 mice were dark adapted for 4 h
and then given 1-µl eye drops of 0.5% atropine (Allergan);
after 10 min, mice were placed in a black box and exposed
to light pulses of 12,000 lux having durations of 2 min (for
details, see Gargini et al., 2017). After light induction, the
animals were assigned to one of the following experimental
protocols:
Protocol I: Acute Administration of Myriocin by
Intravitreal Injection (i.v.)
Mice were anesthetized with i.p. Avertin (0.5 g/mL 2,2,2-
tribromoethanol in ter-amylic alcohol; 20 µl/g body weight).
Using a surgical microscope, 1 µl of a 1.88 or 10 mM solution
of Myriocin in DMSO was injected into the right vitreous
body using a 30-gauge (0.3 × 8 mm) metal needle connected
by a plastic tube to a 10-µl glass Hamilton syringe driven
by an oil microinjector. The 7-fold dilution, considering the
vitreous volume, leads to putative concentration of Myriocin
of 0.27 and 1.43 mM, respectively. Left eyes were injected
with an equal volume of DMSO. After 24 h, the retinas
were isolated from animals under deep anesthesia. Retinas
from n = 3 mice were fixed in 4% paraformaldehyde (PFA),
rinsed in phosphate buffer (PB) 0.1 M, pH 7.4, and stained
with ethidium homodimer to reveal cell nuclei. The outer
nuclear layer (ONL) was imaged at a Leica TCS-SL confocal
microscope using a 568 laser; 12 fields (250 µm × 250 µm)
regularly distributed along the retinal surface were imaged and
subsequently used to count the nuclei of pycnotic photoreceptors,
corresponding to degenerating cells with highly condensed
DNA. This method was used as in previous studies (Strettoi
et al., 2010, PNAS) as it allows estimating the direct reduction
effect of Myriocin on the rate of apoptotic cell death of
photoreceptors. The average density of pycnotic cells per retina
was calculated and the global average value was established
for each experimental group (i.e., Myriocin and corresponding
controls). Data were compared statistically using Sigmastat
Software. Left and right retinas of n = 16 additional mice, injected
with 10 mM Myriocin as above, were quickly isolated in cold
ACSF and analyzed by HPCL-MS (n = 8 mice) and Western
blot (WB) assay (n = 3) as described below. Animals were
killed by cervical dislocation or anesthetic overdose immediately
after eye removal.
Protocol II: Sub-Chronic Administration of Myriocin
by Intraperitoneal Injection (i.p.)
Immediately after light induction, the animals were further
subdivided randomly into two groups, a treatment group that
received 1 mg/kg/day of Myriocin and a control group that
received the vehicle (DMSO). In both cases, the animals were
treated for 5 days and, at the end, used for functional analysis
(ERG), biochemistry (WB), and immunohistochemistry. At the
end of the experimental protocol, the animals were examined
to exclude major adverse effects of the treatment (such as the
presence of cataract, body weight loss, shaggy fur, or altered
sensitivity to anesthesia).
Electroretinogram (ERG) Recordings
Animals were anesthetized with 20% Urethane (Sigma Aldrich,
Milan, Italy), used at a concentration of 0.1 ml/10 g body weight.
ERGs were recorded from dark-adapted mice using coiled gold
electrodes making contact with the cornea moisturized by a thin
layer of gel. Pupils were fully dilated by the application of a
drop of 1% atropine (Farmigea, Pisa, Italy). Light stimulation and
data analysis were as previously described in detail (Piano et al.,
2016). Scotopic ERG recordings were average responses (n = 5)
to flashes of increasing intensity (1.7 × 10−5 to 377 cd∗s/m2,
0.6 log units steps) presented with an inter-stimulus interval
ranging from 20 s for dim flashes to 1 min for the brightest
flashes. Isolated cone (photopic) components were obtained by
superimposing the test flashes (0.016 to 377 cd∗s/m2) on a steady
background of saturating intensity for rods (30 cd/m2), after at
least 15 min from background onset. The amplitude of the a-wave
was measured at 7 ms after the onset of the light stimulus and the
b-wave was measured from the peak of the a-wave to the peak of
the b-wave.
The leading edge of the a-wave was fitted to the model of
the activation phase of the rod G-protein transduction cascade
(Lamb and Pugh, 1992) according to the following equation:
F(t) = exp[−1/28A(t − teff )2] (1)
where F(t) is the fraction of the circulating current normalized
to its dark value, A is the amplification factor with the units
of s−2/8, expressed in terms of the gain parameters of the
cascade stages, and teff is inclusive of any delay contained
in both the response and the instrumentation. Further details
for the application in the RP animal model are given in
Gargini et al. (2007).
Oscillatory potentials (OPs) were also measured in both
scotopic and photopic conditions. OPs were extracted digitally
by using a fifth-order Butterworth filter as previously described
(Hancock and Kraft, 2004; Lei et al., 2006). The peak amplitude
of each OP (OP1–OP4) was measured. The ERG data for each
condition of light induction were collected from at least six
different animals.
Western Blot
Retinas from Tvrm4 mice were lysed in modified RIPA buffer as
described before (Piano et al., 2019) and protein was quantified
with the Bradford assay (Bio-Rad). For each experiment
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performed, three different samples (each one composed of both
retinas mixed together) for each experimental group were loaded
on the gel, each from an animal previously used for ERG
recordings. Proteins (25 µg) were separated onto a pre-cast
4–20% polyacrylamide gel (Mini-PROTEAN R© TGX gel, BioRad)
and transferred to PVDF membranes (Trans-Blot R© TurboTM
PVDF Transfer packs, Bio-Rad). Membranes were blocked with
5% of non-fat dry milk (Bio-Rad) diluted in Tris-buffered saline
(TBS, 20 mM Tris–HCl, pH 7.5, 150 mM NaCl) with 0.1%
Tween 20. Primary antibodies against rhodopsin (cod. R5403,
antibody concentration: ∼1 mg/ml, working dilution1:1000,
Sigma Aldrich), cone-opsin blue and cone-opsin red/green
incubated altogether (cod. AB5407 and AB5405, respectively
antibodies concentration 1 mg/ml, working dilution 1:500,
Millipore), caspase-3 (cod. sc-7272, antibody concentration:
200 µg/ml, working dilution 1:100, Santa Cruz Biotechnology),
and Sod1 (cod. SAB5200083, antibody concentration 1 mg/ml,
working dilution 1:500, Sigma Aldrich) were incubated overnight
at 4◦C. After performing three washings for 10 min each in T-TBS
(TBS buffer with 0.1% of Tween-20), membranes were incubated
with secondary antibodies (anti-mouse or anti-rabbit HRP
conjugated, cod. AP308P or AP147P, respectively, antibodies
concentration 1 mg/ml, working dilution 1:5000; Sigma Aldrich)
for 2 h at room temperature. The immunoblot signal was
visualized by using an enhanced chemiluminescence substrate
detection system (LuminataTM Forte Western HRP Substrate,
Millipore). The chemiluminescent images were acquired by
Chemidoc XRS+ (Bio-Rad). Densitometry was undertaken using
Bio-Rad ImageLab software.
Each protein of interest for the study was normalized for total
protein content by using the Stain Free Technology (Bio-Rad)
(Gürtler et al., 2013). To optimize the number of animals and
the use of samples obtained, in some cases different proteins were
analyzed on the same membrane following a stripping procedure
preceded by three washings (10 min each) in glycine buffer, pH 2,
followed by three washings in T-TBS and blocking in 5% of non-
fat dry milk. The incubation of primary and secondary antibodies
was performed with the same protocol described above.
Tissue Preparation, Histology, and
Immunocytochemistry (IHC)
For retinal histological studies, mice were deeply anesthetized
with intraperitoneal injections of 0.1 ml/5 g body weight Avertin
as described above, their eyes quickly enucleated, and the animals
killed by cervical dislocation. Eyes were labeled on the dorsal
pole, the anterior segments were removed to obtain eye cups
and fixed in 4% paraformaldehyde (PFA) in 0.1 M phosphate
buffer, (PB), pH 7.4, for 30 min or 1 h, at room temperature.
Eye cups were washed extensively in PB, infiltrated in 30%
sucrose in PB at 4◦C, frozen in Tissue-Tek O.C.T. compound
(4583, Sakura Olympus, Italy) using cold isopentane and stored
at −80◦C until use. The eyes were used to prepare retinal
whole mounts, in which the retina was separated from the
pigment epithelium and flattened by making four radial cuts
toward the head of the optic nerve, maintaining a reference
on the dorsal pole. Areas of maximum photoreceptor loss
were imaged on retinal whole mounts stained with 0.2 mM
ethidium homodimer (Strettoi et al., 2010) and mounted with the
photoreceptor side facing the coverslip. IHC on whole mounts
was performed following Barone et al. (2012), by incubation in
(a) block solution with 0.3% Triton X-100, 5% goat serum in
0.01 M phosphate buffer saline (PBS); (b) anti cone-arrestin (cod.
AB15282, 1 mg/ml; working dilution 1:1000) primary antibody,
overnight at 4◦C; and (c) anti-rabbit 568-conjugated secondary
antibody (cod. SAB4600310, 2 mg/ml, working dilution 1:5000).
After rinsing in PBS, specimens were mounted in Vectashield
(H-1000; Vector Laboratories, Burlingame, CA, United States)
and coverslipped.
Ethidium-stained retinal whole mounts were examined with
a Leica TCS SL confocal microscope equipped with a 568-
nm laser using a 40×/1.25 oil objective. ONL series (n = 10
images along the z axis, encompassing the outermost 10 µm)
and having a size of 250 × 250 µm were acquired for each
retinal samples along the dorsoventral and peripheral axis (n = 12
fields/retina), using identical acquisition parameters for treated
and control samples. Pycnotic profiles (corresponding to actively
dying photoreceptors) were counted on projection images of
each confocal series using the manual object counting tool of
Metamorph. Counts were averaged and statistically compared
using SigmaStat software.
Low-magnification images of retinal whole mount for cone-
arrestin preparations were obtained with the Nikon Ni-E
microscope using CFI plan fluor 10×/0.3 NA objective, with
16 mm working distance; images were tiled with Nis “Tiles
and Positions” software to reconstruct the entire retinal surface.
Areas of maximum photoreceptor loss were measured on full
retinal montages saved as tiff files and transferred to an ImageJ
analyzer. Images were homogeneously thresholded for brightness
and the darkest, central region surrounding the optic nerve
head (ONH) was automatically tracked and measured. This
method was chosen as, at advanced stages of degeneration, cone-
arrestin staining highlights clearly the dark, central area devoid
of cones, allowing a quick and reproducible measurement of
the extension of this zone in treated and control cases. This
zone coincides with the central part of the retina where pycnotic
(dying) photoreceptors are visible at early stages.
Ceramide Content
The third group of retinas from light-induced Tvrm4 mice,
injected intravitreally with 10 mM Myriocin, as described in
protocol 1, was used for paired ERG recordings and biochemical
assessment of retinal ceramides. Freshly isolated retinas were
rinsed in ACSF, placed in Eppendorf tubes and weighed on an
analytical balance. The entire procedure took less than 2 min;
samples were then snap frozen on dry ice stored at −80◦C until
use. Animals were killed by cervical dislocation immediately
after eye removal.
The analysis and the extraction procedure from the retina
sample for the determination of sphingolipids were carried out
as already described (Platania et al., 2019). Briefly, retinas were
homogenized in the TissueLyser (Qiagen, Hilden, Germany) and
then aliquoted for the extraction of sphingolipids. Sphingolipids
were extracted using a mixture of water/methanol/chloroform
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(1:6:3, v/v/v). The analytical system consisted of a UPLC
Dionex 3000 UltiMate (Thermo Fisher Scientific, United States)
connected to an ABSciex 3200 QTRAP with electrospray
ionization TurboIonSprayTM source (AB Sciex S.r.l., Milan,
Italy). Quantitative sphingolipid determination was performed
by multiple reaction monitoring (MRM) using as internal
standard C12 ceramide. The separation was carried out
on a reversed-phase BEH C-8 10 × 2.1 mm, 1.7 µm
particle size (Waters, Milford, MA, United States) by mixing
eluent A (water + 2 mM ammonium formate + 0.2%
formic acid) and eluent B (methanol + 1 mM ammonium
formate+ 0.2% formic acid).
Statistical Analysis
Statistical comparisons for ERG and WB analysis were performed
with analysis of variance (ANOVA) one- or two-way test followed
by Bonferroni-corrected t test using Origin Lab 8.0 software
(Microcal, Northampton, MA, United States).
RESULTS
Two studies previously published by the authors (Strettoi et al.,
2010; Piano et al., 2013) showed that ocular administration of
Myriocin, through instillation of nanosphere-based eye drops,
was effective in slowing down the primary degeneration of rods
as well as the degeneration of cones in rd10 mutants, mimicking
typical, autosomal recessive RP. Current literature correlates the
mechanism of action of Myriocin to the reduction of long-chain
ceramides, mediated by the inhibition of the de novo synthesis of
these important bioactive sphingolipids (Sanvicens and Cotter,
2006; German et al., 2006; Ranty et al., 2009; Kurek et al., 2017).
To verify whether this therapeutic approach can be considered
mutation-independent, we administered Myriocin to the Tvrm4
mouse, which carries a different pathogenic mutation, with a
different transmission modality compared to the rd10 mutant.
Pilot experiments were done following the protocol previously
used on rd10 mutants and based on a single intraocular
administration of Myriocin, as this route was proven by us
to produce readily-measurable retinal effects. Two-month aged
animals were exposed to a strong white light for 2 min to
trigger retinal degeneration; after 24 h, Myriocin was injected
in the vitreous body of the right eye. The left eye, injected
with vehicle, served as control. Figure 1 illustrates whole-
mount retinas stained with ethidium and imaged at the
ONL (Figures 1A,B): the dark areas are zones of decreased
fluorescence corresponding to thinning of the ONL and of lost
missing photoreceptors. The extension of degenerated zones
(circled in green) is visibly reduced in the retina treated with
Myriocin with respect to the control side. Coherently, the
number of pycnotic profiles (corresponding to condensed nuclei
of actively dying photoreceptors) illustrated in Figures 1C,D is
lower in retinas treated with Myriocin than in controls. The bar
graph in Figure 1E shows an average decrement of over 1/3
dying photoreceptors in the retina of Myriocin-injected mice. As
for the rd10 mutants used in the previous study (Strettoi et al.,
2010), also in acutely treated Tvrm4 animals, the retinal function
was tested by recording the ERG response. The experimental
group shows a collective trend toward a higher conservation
of the amplitude of the scotopic b-wave in Myriocin-injected
mice, however, the difference with controls reaches statistical
significance (Figure 1F).
To increase the chances of retinal rescue, we tested the
effects of a single intraocular injection of 10 mM Myriocin
by measuring in the same mice both retinal function by
ERG recordings and total ceramide levels assessed by HPL-
MS. Figures 2A,B illustrate the sensitivity curve of scotopic
and photopic ERG, respectively, recorded from animals in
which the right eye was injected with 10 mM Myriocin (red
dots) and the left eye with vehicle (black dots); Figure 2C
shows retinal ceramide levels measured in the same animals.
Effective recovery of a retinal function cannot be demonstrated
FIGURE 1 | Myriocin intravitreal injections in Tvrm4 mice. (A,B) Montages of images of whole-mount retinas stained with ethidium nuclear dye (red fluorescence).
The focal plane is on the outer nuclear layer (ONL). Darker zones (green-encircled) indicate areas where photoreceptors have degenerated and their nuclei are
missing. Larger degenerating zones are labeled with larger asterisks (*). The Myriocin-injected side shows dark zones that are visibly smaller (labeled with smaller
asterisks) and less numerous compared to the control. (C,D) High magnification of the ONL of retinal whole mounts as those shown in A and B. Bright red nuclei
belong to photoreceptors that entered in a stage of DNA condensation (pyknotic nuclei), visibly less numerous in the Myriocin-injected compared to the control eye.
Imaged fields have consistent eccentricity and have been acquired with identical confocal microscope settings. (E) In the underlying bar graph, the average number
of pyknotic nuclei is compared in retinas treated with Myriocin (red bars) and retinas treated with vehicle (black bars). Measurements are from three different mice
(n = 3). (F) Sensitivity curve of the scotopic b-wave amplitude in Myriocin-treated (red squares) and vehicle-treated eyes (black circles) (n = 3). Bar values represent
mean ± SEM.
Frontiers in Neuroscience | www.frontiersin.org 5 May 2020 | Volume 14 | Article 372
fnins-14-00372 May 4, 2020 Time: 17:57 # 6
Piano et al. Therapeutic Approach for RP
(mainly due to the high variability encountered). Yet, an inverse
correlation between the preservation of retinal light-responses
and retinal ceramide content is observable (Figure 2D), albeit
the finding does not reach statistical significance. The analysis
of individual animals shows that when the amplitude of the
ERG response in the eye treated with Myriocin is higher
than in the eye injected with DMSO, ceramide levels are
lower in Myriocin-treated eye than in the vehicle-treated
one (sample no. 5). On the other hand, sample no. 9,
in which the treatment was not effective, shows that the
amplitude of the ERG is lower in the eye with higher
ceramide levels. These data, showing a high individual variability,
nevertheless indicate a direct correlation of retinal ceramide
levels and degeneration and death of photoreceptors in Tvrm4
mutants (Figure 2D).
To test the possible therapeutic efficacy of Myriocin on a
longer time scale, and considering (a) the impossibility to use
repeated ocular administrations in mice and (b) the relatively
quick rate of central retinal degeneration in Tvrm4 mutants
(Gargini et al., 2017), we delivered Myriocin by intraperitoneal
(i.p.) injections at the dose of 1 mg/kg/day for 5 days. The dose,
route, and protocol of administration were based on existing
literature (Glaros et al., 2007; Glaros et al., 2010; Lee et al., 2012).
The results obtained by recording the ERG in Tvrm4 animals
exposed to light and treated via i.p. with Myriocin or vehicle,
for 5 days, are shown in Figure 3. The bar graph shown in
A compares the amplitude of the scotopic b-wave obtained
from Tvrm4 animals where the degeneration was not induced
(green bar—healthy control) with the two groups of animals
exposed to light (pathological phenotype) treated with the
vehicle (black bar) and with Myriocin (red bar). Figures A–C
show that the treatment with Myriocin is effective in reducing
retinal damage compared to animals treated with the vehicle
alone, although photoreceptor preservation is not complete (Ctr
vs. DMSO p = 0.0008; Ctr vs. Myr p = 0.006). Figure 3B
shows that the amplitude of the b-wave is significantly larger
(p = 0.02112; p = 0.02744; p = 0.01, respectively) in the group
of animals treated with Myriocin (n = 8, red dots) compared
FIGURE 2 | Correlation between the decrease of ceramide content and functional recovery. (A,B) Sensitivity curve, respectively, of scotopic and photopic b-wave
amplitude as a function of light flashes of increasing intensity. Although not significantly, the amplitude of the ERG response is increased in the eyes injected with
Myriocin (red dots) compared to the eyes treated with the vehicle (black dots). Values represent mean ± SEM (n = 12; 11). (C) Bar graph showing quantification of
Ceramide content in the same retinal samples used for ERG analysis. The value represents mean ± SEM (n = 9). (D) Correlation between retinal ceramide levels and
functional activity. The bar graph on the left shows the scotopic and photopic b-wave amplitude recorded from Tvrm4 mice injected with 10 µM Myriocin in the right
eye (red bars) and with vehicle in the left eye (black bars); representative (i.e., average-size) traces recorded at the highest luminance used (377 cd*s/m2) are shown
in the squared boxes on the right. The bar charts in the right of the panel show HPLC-MS quantification of ceramide content in the same retinas used for the ERG
analysis. A correlation between the functionality of retinal neurons and ceramide levels is noted, even in cases when Myriocin does not show a protective effect: for
instance, animal 5 has a larger ERG response of the eye treated with Myriocin, which corresponds to reduced levels of ceramide; animal 9 shows a smaller
amplitude of the ERG in the Myriocin-treated eye, which, however has a higher ceramide content, possibly as a result of improper eye injection procedures.
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FIGURE 3 | Functional recovery in Tvrm4 mice after Myriocin intraperitoneal (i.p.) treatment. (A) The bar graph shows the scotopic b-wave amplitude measured at
the highest luminance in non-induced control animals (green bar), in animals treated, after light induction, with vehicle (black bar), or with Myriocin (red bar). (B) The
sensitivity curve of b-wave amplitude as a function of luminance shows a significant increase in Myriocin-treated versus control group. (C) The sensitivity curve of
a-wave amplitude as a function of luminance shows a significant increase in Myriocin-treated versus control group. The inset represents an example of ERG traces
recorded at the highest luminance used (377 cd*s/m2). (D) Scotopic OPs obtained from ERG traces; the bar graph shows that only the OP1 relative to
photoreceptor activity is significantly larger in Myriocin-treated mice with respect to the control mice. (E) Photopic ERG recordings from the not light-exposed Tvrm4
mice (green bar), vehicle-treated (black bar), and Myriocin-treated (red bar) mice. (F) The sensitivity curve of b-wave amplitude as a function of luminance shows a
tendency to be larger in the Myriocin-treated group with respect to the control group. (G) Representative example of ERG traces recorded at the highest luminance
used (377 cd*s/m2) superimposed on a steady background (30 cd/m2). (H) Photopic OPs obtained from ERG traces. The value represents mean ± SEM; *p ≤ 0.05,
**p ≤ 0.01, ***p ≤ 0.001.
to the group of animals treated with the vehicle (n = 7, black
dots). Similarly, Figure 3C shows that also the amplitude of
the a-wave is significantly higher in the animals treated with
Myriocin with respect to the vehicle group (p = 0.018; p = 0.0093;
p = 0.01, respectively); this effect is also confirmed by the a-wave
analysis according to Lamb and Pugh (1992). The amplification
parameter (A, s−2/8) and the effective delay of the responses
(teff ) are shown in Tables 1, 2. It can be observed that the
amplification factor is significantly reduced and that the total
delay is substantially increased in the group treated with the
vehicle alone with respect to the Myriocin-treated group and
also with respect to the healthy control; the analysis also shows
that the injection of Myriocin is effective in restoring the A
parameter near the physiological condition. Figure 3D shows
that the OP amplitude shows a significant increase, mainly in
the OP1 (directly correlated with the function of photoreceptors)
in Myriocin-treated mice with respect to the vehicle group
(p = 0.048).
Photopic ERG recordings are illustrated in Figures 3E–H;
massive degeneration of the cones in the Tvrm4 mutant results
in a significant reduction of the photopic b-wave amplitude with
respect to the healthy control mice (Ctr vs. DMSO; p = 0.00054).
The treatment with Myriocin shows a tendency, although not
significant, to preserve the amplitude of the b-wave due to the
activation of cone photoreceptors. The analysis of photopic OPs
shows no differences between the two groups of mice.
The retinas obtained from the animals used for
electrophysiological recordings were processed for
TABLE 1 | Average value of amplification factor (A) of the a-wave measured at
14000. photoisomerization*rod−1 (8).
Experimental
Group
A (s−2/8) Mean ± St.
Err.
P value
(calculated
respect to
ip-DMSO)
P value
(calculated
respect to No
light-exposure)
ip-DMSO 4.258 ± 0.45056
ip- Myr 9.56067 ± 1.13184 0.0066** N.S. (P > 0.05)
No
light-exposure
9.7215 ± 0.97015 0.0092**
TABLE 2 | Average value of effective delay (Teff) of the a-wave measured at 14000
photoisomerization*rod−1 (8).
Experimental
Group
Teff (s) Mean ± St.
Err.
P value
(calculated
respect to
ip-DMSO)
P value
(calculated
respect to No
light-exposure)
ip-DMSO 0.01097 ± 3.61E-4
ip- Myr 0.00996 ± 2.27E-4 0.036* 0.00001***
No
light-exposure
0.00772 ± 1.42E-4 0.00007***
immunohistochemistry and biochemistry experiments.
Figures 4A,B show a retina obtained from an animal treated
with Myriocin and one treated with the vehicle stained with
cone-arrestin antibodies; the central area of degeneration
(highlighted by the green outline) is largely reduced in the
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FIGURE 4 | Reduction of the photoreceptor-degeneration area after i.p. administration of Myriocin. (A,B) Representative images of retinal whole mounts obtained
from control and Myriocin-treated mice obtained by anti-cone arrestin immunostaining (red fluorescence). The green lines surround the area affected upon the
induction of the mutation by light exposure. (C) Quantification of the affected area calculated as a percentage of the total retinal area from three different experiments
(shown in the insert bar graph, C1), showing a significant reduction in animals treated with Myriocin (red bars) compared to animals treated with vehicle (black bars).
The values reported in the main bar graph represent global averages of all the experiments; Values are shown as mean ± SEM (n = 3, for each analyzed group);
*p ≤ 0.05.
retina from the animal treated with Myriocin with respect
to the control. Measurement of the degeneration zone with
respect to the total retinal area, reported as a percentage, is
shown in the bar graph of Figure 4C, proving how systemic
administration of Myriocin for 5 days significantly reduces
(p = 0.03471) the area of photoreceptor death. These data also
indicate the ability of Myriocin or of an active metabolite to
cross the blood–retinal barrier and reach the retina, which
is known to weaken in neurodegenerations, thus allowing
the passage of molecules useful for therapeutic treatment
(Acharya et al., 2017).
In order to confirm the rescue effects described above, we
measured the levels of rhodopsin and of blue and red/green
cone-opsins by WB analysis (Figures 5A–C). The bar graph
in Figure 5B shows that after induction of the mutation
by light exposure, rhodopsin levels are significantly reduced
FIGURE 5 | Preservation of rhodopsin and cone-opsins level following treatment with Myriocin. (A) Representative example of WB experiment of rhodopsin and
cone-opsins content. (B) Quantification by optical densitometry of rhodopsin levels in Tvrm4 animals not exposed (green bar) and treated with Myriocin (red bar) or
with vehicle (black bar) by both intravitreal and intraperitoneal injection after light induction. The bar graph shows that the levels of rhodopsin are significantly reduced
in the animals treated with DMSO with respect to the non-exposed controls; i.p. treatment with Myriocin results in a rhodopsin content significantly higher with
respect to the group of animals treated with vehicle. (C) Quantification by optical densitometry of cone-opsins levels in Tvrm4 animals not exposed (green bar) and
treated with Myriocin (red bar) or with vehicle (black bar) by both intravitreal and intraperitoneal injection after light induction. The bar graph shows that the levels of
cone-opsins are significantly reduced in the animals treated with DMSO with respect to the non-exposed control. Treatment with Myriocin, by both routes of
administration, leads to an increase in cone-opsins levels, although not statistically significant. Values are shown as mean ± SEM (n = 3, for each analyzed group);
*p ≤ 0.05, ***p ≤ 0.001.
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FIGURE 6 | Systemic Myriocin treatment increases the level of Sod1 protein. (A) Representative example of WB experiment of caspase-3 and Sod-1 content.
(B) Quantification by optical densitometry of caspase-3 levels in Tvrm4 animals treated with Myriocin (red bar) or with vehicle (black bar) compared to the level in
non-exposed mice (green bar). The bar graph shows that the levels of the pro-apoptotic marker caspase-3 are reduced in the group of animals treated with
Myriocin. (C) Quantification by optical densitometry of Sod1 levels in Tvrm4 animals not light-induced (green bar), treated with vehicle (black bar), or treated with
Myriocin (red bar). The bar graph shows that the levels of the anti-oxidant enzyme Sod1 are significantly increased in the group of mice treated with Myriocin, with
respect to both the group of non-degenerate control animals and the group of mice treated with the vehicle alone. Values are shown as mean ± SEM (n = 4, for
each analyzed group); ∗p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. (B) Representative example of WB experiment.
compared to the levels measured in a healthy control animal
(Ctr vs. i.v.-DMSO p = 0.012; Ctr vs. i.p.-DMSO p = 0.0004).
The graph also shows that previously described i.v. treatment
with Myriocin is not sufficient to preserve a number of rods
such as to result in a significant increase in rhodopsin content;
on the other hand, i.p. treatment with Myriocin is effective
in saving a larger number of photoreceptors, resulting in a
significant increase of this protein (i.p.-DMSO vs. i.p.-Myriocin
p = 0.035). Figure 5C shows a similar trend also for the cone-
opsins levels, which are significantly reduced in the induced
animals treated with the vehicle alone with respect to healthy
controls (Ctr vs. i.v.-DMSO p = 0.033; Ctr vs. i.p.-DMSO
p = 0.014). Again, although not significantly, the treatment with
Myriocin shows a trend toward cone preservation as shown in
the bar graph of Figure 5C. These data are in agreement with
ERG recordings that show a significant recovery only for the
scotopic protocol.
The levels of caspase-3, a specific marker of apoptosis, were
also measured by WB assay (Figure 6A), to confirm the reduction
of common apoptotic pathway activation. Figure 6B shows
how the levels of caspase-3 are increased in degenerating retina
with respect to the control healthy group. Furthermore, i.p.
treatment with Myriocin significantly reduces (p = 0.0057) the
levels of caspase-3 compared to those obtained from control
animals (n = 4/experimental group). This result confirms the
anti-apoptotic effect of Myriocin, at the retinal level, also when
administered systemically.
Finally, to assess whether Myriocin (or any derivative
metabolites) could act via signaling pathways known to
act in inherited retinal degeneration, we analyzed retinal
protein levels of Sod1, one of the main enzymes of the
physiological anti-oxidant system. Figure 6C shows how, in
retinas obtained from light-induced Tvrm4 mice, the Sod1
content is significantly reduced with respect to the control
healthy mice (Ctr vs. i.v.-DMSO; p = 0.0008; Ctr vs. i.p.-DMSO;
p = 0.008). This result indicates a reduced ability of the damaged
photoreceptors to remove ROS from the cellular environment.
In both treatment protocols (i.v. and i.p.) with Myriocin, it is
possible to note an increase in Sod1 levels toward physiological
ones, although only in the case of i.p. administration is this
increase significant (p = 0.035).
These results indicate that Myriocin, administered i.p., directly
or by means of yet unknown metabolic derivatives, reaches the
interior of the eye and exerts a protective effect on RP-like
retinal degeneration. Besides the known activity as a suppressor
of ceramide de novo synthesis and an anti-apoptotic agent,
Myriocin could act, in medium and long-term treatments, on
other cellular pathways, including induction of detoxifying anti-
oxidant systems.
DISCUSSION
Previous studies have shown that increased ceramide levels in the
rd10 animal model of autosomal recessive RP are in temporal
association with the process of photoreceptor demise and that
in vivo inhibition of de novo ceramide biosynthesis delays
effectively this process (Strettoi et al., 2010; Piano et al., 2013).
This observation supports the notion that this sphingolipid is
involved in the neurodegenerative process taking place in RP. The
results are in agreement with the increased ceramide levels found
in tissues from individuals with other pathologies leading to
apoptosis, such as brain tissue from Alzheimer’s disease patients
and thus provide additional evidence that elevated ceramide is
a common pathogenic factor of a variety of neurodegenerative
diseases (Han et al., 2002; He et al., 2009; Kurek et al., 2017). Both
in vitro and in vivo studies on various animal models confirm
that ceramide is involved in processes that trigger apoptotic death
of photoreceptors and that treatments aiming at to reducing
ceramide content are beneficial to cell viability and function
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(Acharya, 2003; Acharya and Acharya, 2005; German et al., 2006;
Sanvicens and Cotter, 2006; Rotstein et al., 2010).
The present study suggests that Myriocin, a selective inhibitor
of SPT, the rate-limiting enzyme of ceramide biosynthesis,
exerts rescue effects on the (rather acute) retinal degeneration
process occurring in Tvrm4 mice, carrying a dominant mutation
of rhodopsin inducible by light in adulthood and therefore
completely different from the rd10 mutants previously employed.
We show that, similarly to rd10 mice, rescue effects obtained
with a single intraocular injection of 1.88 mM Myriocin reduce
the number of pycnotic photoreceptors, but this is not sufficient
to efficiently rescue the ERG response (Strettoi et al., 2010)
and does not change reproducibly ceramide levels (data not
shown). Increasing the dose of Myriocin to 10 mM results in a
similarly limited recovery of visual function and reveals single-
case correlations between ERG amplitude and levels of retinal
ceramide, without reducing it significantly on averaged data.
WB analysis shows a Myriocin-related tendency to restore the
levels of enzymes involved in apoptotic processes (caspase 3) and
oxidative stress (Sod1) toward physiological values, indicating
a reduction in the degenerative process. Most likely, the lack
of functional effects after intravitreal treatment with Myriocin
depends on the short duration of the treatment that fails to
save a number of photoreceptors large enough to affect a mass-
recording measurement such as the ERG. Moreover, the intrinsic
variability in the size of the light-induced, degenerating area
typical of the Tvrm4 phenotype makes the acutely induced
and treated model quite complex for quantitative mass assays,
despite the fact that we invariably use the contralateral, vehicle-
treated eyes as controls. Conversely, a measurable decrement in
the number of degenerating photoreceptor profiles (which are
counted with single-cell resolution) is achieved with a single i.v.
injection of 1.88 mM Myriocin, demonstrating efficacy in the
acute phase of degeneration as already shown on the rd10 model
(Strettoi et al., 2010).
To extend the time window of Myriocin treatment and
appreciate the likely beneficial effects on the Tvrm4 retinal
phenotype, we chose sustained (5-day) treatment achieved by
the systemic administration of the drug by intraperitoneal
injections (Osuchowski et al., 2004). Intraperitoneal treatment
did not cause any adverse effect at general and ocular level
although specific toxicity studies will be necessary in the future.
Indeed, sustained, i.p. administration of Myriocin in Tvrm4
mice effectively reduces the size of the central-degenerating
retina, rescues rhodopsin levels, and preserves the scotopic ERG.
These results strongly suggest that Myriocin, or some active,
yet unknown metabolite, are able to permeate the blood–retinal
barrier, which, in these animals, could already be damaged
due to the degenerative processes in progress and reduce the
processes that lead to the death of photoreceptors. Indeed,
levels of activated caspase-3 protein are reduced as well. Our
experiment indications about levels of physiological defense
pathways against the oxidative stress implicated in secondary
cone degeneration (Usui et al., 2011) show that Myriocin i.p.
treatment is associated with a significant increase in the content
of the cytosolic isoform of retinal Sod1. Hence, Myriocin is not
only an effective anti-apoptotic agent acting by inhibiting SPT
and decreasing ceramide levels, in turn involved also in ROS
generation (Sanvicens and Cotter, 2006) but is also capable of
increasing the physiological anti-oxidant defenses by stimulating
the synthesis of the key enzyme Sod1.
Although the efficacy of Myriocin as an anti-apoptotic and
as a regulator of the cell cycle has already been proven in other
tissues by means of either local (Reforgiato et al., 2016) and
systemic administration to target cancer cells (Lee et al., 2012)
or lipid metabolism in an animal model of type I diabetes (Kurek
et al., 2017), our study is the first that demonstrates the ability
of Myriocin, or of some active metabolite, to act effectively on
the retina, an outpost of the brain, even when administered
systemically, exerting a measurable anti-degenerative action and
activating local anti-oxidant defenses. An anti-inflammatory
benefit on retinal survival is not to be excluded, given the
proven action of Myriocin as an immunosuppressant and anti-
inflammatory agent (Caretti et al., 2014) and the increasing
evidence of a contribution of inflammation-immune response
on worsening of retinal phenotype in inherited photoreceptor
degeneration (Zabel et al., 2016; Guadagni et al., 2019).
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